ECM
ATYR

ExodusPoint Capital Management’s aTyr Pharma ATYR Stock Holding History

ExodusPoint Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-48,227
Closed -$146K – 2058
2025
Q1 		$146K Buy
48,227
+31,441
+187% +$115K ﹤0.01% 1325
2024
Q4 		$61K Buy
+16,786
New +$50.8K ﹤0.01% 1420
2022
Q2 		– Sell
-13,456
Closed -$72K – 2542
2022
Q1 		$72K Buy
+13,456
New +$76.2K ﹤0.01% 2035
2021
Q2 		– Sell
-11,066
Closed -$49K – 2887
2021
Q1 		$49K Buy
+11,066
New +$52K ﹤0.01% 2032

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ExodusPoint Capital Management's ATYR Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of aTyr Pharma (ATYR) in Q2 2025, closing a stake of 48,227 shares — an estimated $146K sold.

ExodusPoint Capital Management first reported a position in ATYR in Q1 2021 and held it in 4 quarters. The position peaked at $146K in Q1 2025. 110 funds tracked by Wall St. Rank hold ATYR as of Q2 2025.

  • ExodusPoint Capital Management reported no remaining aTyr Pharma position as of Q2 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 48,227 aTyr Pharma shares in Q2 2025, an estimated $146K.
  • ExodusPoint Capital Management first reported a position in aTyr Pharma in Q1 2021 and held it in 4 quarters.
  • ExodusPoint Capital Management's aTyr Pharma position peaked at $146K in Q1 2025.
  • 110 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.